Get the latest news, insights, and market updates on ORKA (Oruka Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Oruka Therapeutics Announces New Board Member and Board Transition
Appoints accomplished commercial leader Chris Martin to its Board of DirectorsMENLO PARK, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the appointment of Chris Martin to its Board of Directors. Additionally, Cameron Turtle, DPhil, resigned from the Board effecti Dec 11, 2025 - $ORKA
ORKA-001 Trial Progress and US$180 Million PIPE Financing Might Change The Case For Investing In Oruka Therapeutics (ORKA)
Oruka Therapeutics recently reported its third quarter 2025 results, including a net loss of US$30.28 million, and completed a major US$180 million PIPE financing to extend its cash runway beyond key upcoming clinical milestones. The company also presented promising early Phase 1 results for ORKA-001, suggesting potential for once-per-year dosing and sustained efficacy in treating psoriasis. We’ll explore how the combination of positive interim ORKA-001 data and strengthened financials may... Nov 15, 2025 - $ORKA
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three key readouts: ORKA-001 Phase 2a and 2b (EVERLAST-A and -B), and ORKA-002 Phase 2 ORKA-002 Phase 1 trial ongoing, with data to be presented around YE 2025 ORKA-001 Phase 2a trial enrolling well with data expected 2H 2026 MENLO PARK, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. Nov 12, 2025 - $ORKA
Oruka Therapeutics to Present at Multiple November Investor Conferences
MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation ConferenceDate: Monday, November 10th, 2025Time: 9:00AM ET Stifel 2025 Healthcare ConferenceDate: Tuesday Oct 29, 2025 - $ORKA
Oruka Therapeutics (ORKA) Is Up 33.2% After Announcing $1.25B Shelf Registration and $200M Offering
Oruka Therapeutics, Inc. recently filed two major shelf registrations totaling over US$1.25 billion and announced a US$200 million follow-on equity offering for its common stock. These corporate actions suggest a significant effort to increase financial flexibility, which can influence how investors view the company's ability to fund development and operations. We'll explore how the company's drive to raise substantial capital could shift the investment narrative for Oruka... Oct 10, 2025 - $ORKA
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple